Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2022-05-25 Director's Dealing
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-05-25 English
FORM 3
Director's Dealing
2022-05-25 English
DEFA14A
Board/Management Information Classification · 95% confidence The document is a Supplement to a Definitive Proxy Statement (Schedule 14A) filed with the SEC for the Annual Meeting of Stockholders. It announces a change in the Board of Directors with the election of a new director, Jill DeSimone, and details her background and compensation. The document is not the proxy statement itself but additional materials related to it. The content focuses on board/management changes rather than financial results or other report types. Therefore, the filing type corresponds to Board/Management Information (MANG). The document length is just over 5,000 characters, and it contains substantive information about management changes, not just an announcement or a certification, so it is not RNS or RPA.
2022-05-23 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 21, 2022, by Praxis Precision Medicines, Inc. The key content is the announcement of the election of a new director, Jill DeSimone, to the Board of Directors. It details her appointment, compensation policy, and independence status. There is no financial data or report attached, nor is this a full annual or quarterly report. The primary subject is a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 4042 characters, which is short but contains substantive information about management changes, not just a notice or announcement of a report publication. Therefore, the correct classification is MANG with high confidence.
2022-05-23 English
FORM 4
Director's Dealing
2022-05-18 English
FORM 4
Director's Dealing
2022-05-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.